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cessing in failing hearts. This finding might explain the altered Ca2+-release
from SR as obseivad in human end stage heart failure.
I1016-152I Relative Expression of Ca~dia~T~~p~ninT
Isoforms in Control snd Fsiling Humsn Left
Ventricles
L. Mesnard, J.-J. Mercsdier, D. Logeart, M. Heimburger, G. Butler-Browne,
F.Samson. Facult4 de M6decine de Parfs-Sud, CNRS URA 1159,Le
Plessis Robinson, France, CNRS URA 1448, Paris, Frarrca
Tropcnin Tisa protein of the thin filament of thesarcomere which participates
in the regulation of actin-myosin interaction. We and others have cloned pre-
viously several cDNAs of human cardiac TnT (cTnT) which demonstrated
the multiplicity of cTnT isoforms in the human heart. Four of these isoforms
named TnTl, 2, 3 and 4 result from a combinatorial alternative inclusion of
a 30 and a 15 nt sequence in the 5’ coding region of the cDNAs. In failing
human ventricles, an increased expression of TnT4 has been reported at
the protein level and more recently, RT-PCR experiments showed increased
expression of fetal-type splicing producte in the 5’ region, one of them cor-
responding to TnTl. To clarify this ieeue, we examined the accumulation of
the four TnT mRNA species in 13 failing and 8 control adult left ventricles
using RNaee protection assay and Western blotting. At the mRNA level, the
four iscforms were detected in all samples: TnT3 was the major isoform,
TnT4 a minor isoform and TnTl and 2 were barely detected. At the protein
level, TnT3, 4 and 1 were detected with the same relative abundance as
that seen at the mRNA level. In addition, we detected a fourth TnT species
of faster electrophoretic mobility which could correspond either to a skeletal
TnT isoform or to a short cTNT isoform. We obsenfed a significant increase
in the level of TnT4 mRNA and protein expression in only half of the failing
ventricles compared to controls. At the protein level, TnTl relative abun-
dance wasdeoreased in all the failing samples studied compared to controls.
Conclusion: TnT4 expression in human ventricles seems more related to
individual variations than specific for left ventricular failure; a decrease in
TnTl relative expression maybe more specific for left ventricular failure.
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Angiotensin converting enzyme (ACE) inhibitors are known to improve csr-
diac function in congestive heart failure; however, very little is known if this
effect is associated with similar changes in the subcellular and molecular
mechanisms for Ca2+-handliflg. Since impairment of the sarcoplasmic retic-
ular (SR) Caz+-transporl in the failing hearl plays a critical role in contractile
dysfunction, we examined the effects of a new ACE inhibitor, imidapril, on
the SR Ca2+ transport and gene expression of the Ca2+ pump ATPeee
(SERCA2) in failing hearts due to myooerdial infarction. In this study heart
failure was induced in rats by occluding the coronary artery for 7 weeks;
sham-operated animals served as controls. Both control and experimental
animals were either given imidapril (1 mgik~day) or the vehicle for period of
4 weeks starting at 3 weeks after the coronary occlusion. Hemodynamic as-
sessment revealed a 4-fold increase in left ventricular end diastolic pressure
(LVEDP) whereas the rate of mntraction (+dP/dt) and the rate of relaxation
(-dP/dt) were decreased by58 +3.4 and 82 +2.3% in the infarcted animals,
respectively. The LVEDP in the imidapril-treated animals was increased by
1.8-fold whereas +dP/df and –dP/df were decreased by 20 * 2.1 and 16+
1.8%, respectively.The SRCa2+ uptake wasdepressad by50t065%and 15
to 26% in the untreated and imidapril-treatad infarcted animale, respectively;
the SR Ca2+-pump ATPase activities in the control, untreated-infarcted and
treated-infarcted groups were 13.8 * 1.3, 5.8 + 1.8 and 11.0 + 1.2 &mol
Pi/m@hr.Western blot analysis revealed a 25% decrease in the Ca2+pump
protein in the infarcted animais; this change was completely prevented by
imidaprfl. The SERCA2 mRNA levels were reduced by 50 * 4.5 and 18 *
2.3% in the untreated and treated infarct groups, respectively.These resulte
suggestad that ACE inhibitor’ssuch as imidapril may increase the abundance
of mRNA for SR proteins and thus may prevent the depression in SR Ca2+-
transport andaescoiatsd Cardiacdysfunction in animals with congestive heart
failure.
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Traditional inotropic agente, e.g., those that increase myooardial contraction
through enhanced cyclic AMP at relatively high 02 cost are frequently not
useful in the clinical setting, in part, because mechanical efficiency is not
improved. The goal of this study was to evaluate the effects of a new agent,
i.e., a calcium promoter, BAY y 5959, in 11 conscious dogs, chronically
instrumented for measurement of left ventricular (LV) and arterial pressures,
LVdiameter, wall thickness, coronary blood flow, cardiac output, and arterial
and corona~ sinus Oz before and after heart failure (HF) was induced by
rapid pacing (240 b/rein x 4 wks). Heart rate fell with BAY y 5959 similarly
before (31 + 3%) and after (–33 + 5%) HF. LV dP/dt increased with BAY y
5959 similarly before (72 + 6%) and after HF (69 + 10’Yo).Cardiac output
rose with BAY y 5959 more (p -=0.05) after HF (45 + 7%) than before HF (7
+ 3%). Mechanical efficiency, calculated from cardiac output, pressures and
MVO*, fell (p < 0.05) in HF (from 0.56+ 0.06 to 0.23 + 0.04). BAY y 5959
increased efficiency more (p < 0.05) after HF (0.18 + 0.04) than before HF
(0.06 + 0.03). Thus, the calcium promoter, BAY y 5959, increases inotropic
state and cardiac output in HF, but most importantly increases mechanical
efficiency, making this agent potentially desirable for clinical applications
Whereinotropic support is indicated.
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Congestive Heart Faiiure at an Academic. –
Medicai Center: 1990-1995
M.W. Rich, K. Brooks, P.Luther. Washington University School of Medicine
and the St. Louis College of Pharmacy, St. Louia, MO, USA
To determine the impact of recent clinical tnale and publiehed,guidelines on
the management of congestive hearl failure (CHF) at an academic medical
center, discharge medications in patients (PTS) hospitalized with a primary
diagnosis of CHF in 1990 (N = 109) and 1995 (N = 168) were compared. All
PTS had an echocardiogram and separate analyses were performed in PTS
with impaired (estimated EF c 45%) vs. preserved (EF z 45%) LV aystolic
function.
Resu/ta:The median age was 74 yre, 37.3% were male, and 45.1% were
white. Discharge medications in PTS with eyetolic dysfunction included:
1990 (N= 47) 1995 (N= 108) P
Digoxin 44.7”/0 50.9”/. NS
Diuretic 83.O”A 84.3% NS
ACE inhibitor 7e.7”h 89.e% 0.11
Optimaldose* 24.3”A 81.5% <0,001
Calciumblocker 21.3”A 25.9 ”/o NS
Beta blocker 2.1”/. 15.7”/0 0.031
ACEIor nitrates/hydrsl 80.94A 95.4”/. 0.009
. z targetdow in publishedtrials
Inpatients with presenmd LV function, the use of both ACE inhibitors
(33.9% vs. 52.5%, p = 0.041) and beta blockers (4.8% vs. 23.6%, p = 0.004)
increased significantly from 1990-1995.
Conclusions: In accordance with published guidelines, over gs~o of PTS
with systolic CHF were receiving an ACE inhibitor or hydralazine/nitrates in
1995, a significant increase from 1990. The propotlion of PTS on optimal
dose ACE inhibitore increased 2.5-fold, and there was a 7.5-fold increase in
the use of beta blockers. The use of ACE inhibitors and beta blockers also
increased in PTS with CHF and preserved systolic function. The use of other
medications, including digoxin, did not change during this period.
